Report of Foreign Issuer (6-k)
March 27 2019 - 8:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER
PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES
EXCHANGE ACT OF 1934
For the month of
March
2019
Commission File
Number 333-209744
TODOS MEDICAL
LTD.
(Translation of
registrant’s name into English)
|
1 Hamada Street
Rehovot, Israel 2244427
Tel: (011) (972) 8-633-3964
|
|
(Address
of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
|
|
x
Form
20-F
o
Form
40-F
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
|
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
|
Appointment of Director
In accordance with the joint venture agreement
signed by the Company with Amarantus Bioscience Holdings, Inc. and Breakthrough Diagnostics Inc. on February 27, 2019, Amarantus
was entitled to have a representative appointed as a director of the Company. On March 25, 2019, the Board of Directors of the
Company approved the appointment of Dr. Colin Bier to its Board of Directors.
Dr. Bier, age 72, currently serves as Managing
Director of ABA BioResearch Inc. From September 2013 until 2018, he served as a Corporate Advisor of Amarantus Bioscience Holdings,
Inc. He also served as a Senior Advisor of TVM V Life Science Ventures and NGN Capital. From November 2001 to June 15, 2002, Dr.
Bier served as Chairman of the Board and Chief Executive Officer of Soligenix, Inc. From 1996 through 2008, Dr. Bier was a Director
of Neurochem Inc. Dr. Bier serves as a Director of Lomir Biomedical Inc., a private company, of Mount Sinai Hospital Montreal,
and of Receptagen, a publicly traded company. He has published more than twenty-five scientific articles in his field in peer-reviewed
journals.
Dr. Bier received his Ph.D. in Experimental
Pathology from Colorado State University in 1978 and then pursued additional training in experimental pathology and toxicology
as a Medical Research Council Postdoctoral Fellow and the Dr. Douglas James Fellow in the Department of Pathology, McGill University.
He received his M.Sc. from Long Island University in 1974, and his B.A. from Sir George Williams University in 1967.
Dr. Bier will not be receiving any compensation
at this time for serving as a Director of the Company.
Financial Statements and Exhibits.
The following Exhibits are filed as part of this Report.
Signatures
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
TODOS MEDICAL LTD.
|
|
|
|
By:
|
/s/ Dr. Herman Weiss
|
|
|
Name: Dr. Herman Weiss
|
|
|
Title: Chief Executive Officer
|
|
|
|
Date: March 27, 2019
|
2
Todos Med (CE) (USOTC:TOMDF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Todos Med (CE) (USOTC:TOMDF)
Historical Stock Chart
From Apr 2023 to Apr 2024